R. Guild

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

J. G. Berdeja, Sikander Ailawadhi, Steven Weitman et al. · Journal of Clinical Oncology · 2011 · 36 citations

Relapsed/refractory Mm, Immunology, Pharmacotherapy +17

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Jesús G. Berdeja, Francisco J. Hernandez‐Ilizaliturri, Asher Chanan‐Khan et al. · Blood · 2012 · 28 citations

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan‐Khan, Jeffrey L. Wolf, Mecide Gharibo et al. · Blood · 2009 · 23 citations

Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma

John McCann, Frank V. Fossella, Miguel A. Villalona‐Calero et al. · Journal of Clinical Oncology · 2007 · 21 citations

Immunology, Pathology, Initial Infusion +22

Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.

Penella J. Woll, Kraig Moore, Shailender Bhatia et al. · Journal of Clinical Oncology · 2011 · 17 citations

Surgical Oncology, Cancer Management, Immunology +17